PHA-543,613

PHA-543,613
(IUPAC) ime
	N-[(3R)-1-azabiciklo[2.2.2]okt-3-il]furo[2,3-c]piridin-5-karboksamid
Klinički podaci
Identifikatori
CAS broj	478149-53-0
ATC kod	nije dodeljen
PubChem	11493927
ChEMBL	CHEMBL214268
Hemijski podaci
Formula	C15H17N3O2
Mol. masa	271,314
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C15H17N3O2/c19-15(12-7-11-3-6-20-14(11)8-16-12)17-13-9-18-4-1-10(13)2-5-18/h3,6-8,10,13H,1-2,4-5,9H2,(H,17,19) ; Key: IPKZCLGGYKRDES-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

PHA-543,613 je lek koji deluje kao potentan i selektivan agonist za α7 podtip neuronskih nikotinskih acetilholinskih receptora. On ima visok nivo moždane penetracije i dobru oralnu biodostupnost. Ovaj ligand je u razvoju za moguću primenu u tretmanu kognitivnih deficita kod obolelih od šizofrenije.^[4]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Wishka, D.; Walker, D.; Yates, K.; Reitz, S.; Jia, S.; Myers, J.; Olson, K.; Jacobsen, E. i dr.. (2006). „Discovery of N-(3R)-1-azabicyclo2.2.2oct-3-ylfuro2,3-cpyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship”. Journal of Medicinal Chemistry 49 (14): 4425–4436. DOI:10.1021/jm0602413. PMID 16821801.

Vanjske veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] Wishka, D.; Walker, D.; Yates, K.; Reitz, S.; Jia, S.; Myers, J.; Olson, K.; Jacobsen, E. i dr.. (2006). „Discovery of N-(3R)-1-azabicyclo2.2.2oct-3-ylfuro2,3-cpyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship”. Journal of Medicinal Chemistry 49 (14): 4425–4436. DOI:10.1021/jm0602413. PMID 16821801.

[4]

[1]

[2]

[3]